Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease

  • 18 Accesses

Summary

Antiischemic effects of β1-blocking agents are based on intrinsic negative inotropic and chronotropic properties. Partial β1-agonistic activity, although useful in preserving cardiac function, may counteract such antischemic properties by modulating the intrinsic negative cardiac effects of beta-blockade. To investigate the acute hemodynamic and antiischemic profile of epanolol, a cardioselective β1-antagonist and partial agonist, 20 patients with left coronary artery disease underwent two incremental atrial pacing tests, 45 minutes before (APST I) and 15 minutes after (APST II) 4 mg intravenous epanolol, administered over 5 minutes. Additional measurements were carried out at 1, 3, 5, 10, and 15 minutes after epanolol, at basal and fixed heart rates. Epanolol immediately reduced heart rate with a maximum of 10% at 15 minutes and decreased contractility (Vmax) by 7% (both p<.05), whereas cardiac output fell temporarily by 9% (p<.05). Other hemodynamic parameters did not change, except for a significant 11% reduction in myocardial oxygen demand. Despite comparable pacing conditions, both the double product and contractility decreased significantly less during APST II, resulting in a 17% lower myocardial oxygen consumption (p<.05). Myocardial ischemia was markedly reduced, indicated by normalization of lactate metabolism [lactate extraction 16±7% vs. −7±8% (APST I)], less ST depression (21%), and modulation of LV end-diastolic pressure postpacing (all p<.05 vs. APST I), whereas angina was absent or less in 14 patients. None of the patients reported an adverse effect. Thus, under resting conditions intravenous epanolol induces moderate, short-lasting negative chronotropic and inotropic effects, but does not alter cardiac pump function or vascular resistance, reflecting its additional β1-agonistic properties. Alternatively, during pacing it still reduces ischemia through negative inotropic effects and diminishes myocardial oxygen demand, reflecting its β1-antagonistic profile.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Smith HJ, Holliday SE, Earl CDN, Stribling D. Effects of selective (β1 and β2) and nonselective β-adrenoreceptor antagonists on the cardiovascular and metabolic responses to isoproteronol: Comparison with ICI 141.292.J Pharmacol Exp Ther 1983;226:211–216.

  2. 2.

    Bonde J, Svendsen TL, Lyngborg K, Mehlsen J, Trap-Jensen J. Immediate haemodynamic effects of a novel partial agonist β1-adrenoreceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and patients with ischaemic heart disease.Br J Clin Pharmacol 1987;23:35–40.

  3. 3.

    Omvik P, Lund-Johansen P, Haugland H. Modest antihypertensive effect of epanolol, a beta1-selective receptor blocker with beta1-agonist activity: An acute and long-term hemodynamic study at rest and during exercise and double crossover comparison with atenolol on ambulatory blood pressure.Cardiovasc Drugs Ther 1993;7:125–132.

  4. 4.

    Brower RW, Mey S, Serruys PW. A model of asynchronous left ventricular relaxation predicting the bi-exponential pressure decay.Cardiovasc Res 1983;17:482–488.

  5. 5.

    Remme WJ, Van de Berg MD, Mantel M, et al. Temporal relation of changes in regional coronary flow and myocardial lactate and nucleoside metabolism in humans during pacing-induced ischemia.Am J Cardiol 1986;58:1188–94.

  6. 6.

    Hansson L, Zweifler AJ, Julius S, Hunyor SN. Hemodynamic effects of acute and prolonged β-adrenergic blockade in essential hypertension.Acta Med Scand 1974;196:27–34.

  7. 7.

    Man in 't Veld AJ, Schalekamp MADH. Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma renin activity and plasma norepinephrine in hypertension: The key role of vascular resistance changes in relation to partial agonist activity.J Cardiovasc Pharmacol 1983;5(Suppl 2):S30-S45.

  8. 8.

    Man in 't Veld AJ. Vasodilation, not cardiodepression, underlies the antihypertensive effect of beta-adrenoceptor antagonists.Am J Cardiol 1991;67:13B-17B.

  9. 9.

    Fitzgerald JD, Ruffin R, Smedstad KG, Roberts R, McAinsh J. Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.Eur J Clin Pharmacol 1978;13:81–89.

  10. 10.

    Van den Meiracker AH, Man in 't Veld AJ, Ritsema van Eck HJ, Schalekamp MA. Systemic and renal vasodilation after beta-adrenoceptor blockade with pindolol: A hemodynamic study on the onset and maintenance of its antihypertensive effect.Am Heart J 1986;112:368–374.

  11. 11.

    Armstrong PW, Chiong MA, Parker JO. Effects of propranolol on the hemodynamic, coronary sinus blood flow and myocardial metabolic response to atrial pacing.Am J Cardiol 1977;40:83–89.

  12. 12.

    Prida XE, Feldman RL, Hill JA, Pepine CJ. Comparison of selective (beta1) and nonselective (beta1 and beta2) beta-adrenergic blockade on systemic and coronary hemodynamic findings in angina pectoris.Am J Cardiol 1987;60:244–248.

  13. 13.

    Remme WJ, Kruijssen HACM, Krauss XH, Remme P, Van Hoogenhuyze DCA. Early-phase post-pacing lactate production. A new gold standard for the detection of ischemia in man (abstr).J Am Coll Cardiol 1992;19:337.

  14. 14.

    Remme WJ, De Leeuw PW, Bootsma M, Look MP, Kruijssen HACM. Systemic neurohumoral activation and vasoconstriction during acute myocardial ischemia in humans.Am J Cardiol 1991;68:181–186.

  15. 15.

    Van der Ent M, Remme WJ, Bartels GL, Krauss XH, Van Hoogenhuyze DCA. Acute beta blockade reduces ichemia by modulating systemic and cardiac renin-angiotensin activity (abstr).Eur Heart J 1992;13(suppl):20.

  16. 16.

    Remme WJ, Kruijssen D, Krauss H, Bartels L. Is angina really the gold standard to test interventions in ischemia (abstr)?J Am Coll Cardiol 1993;21(suppl):456.

  17. 17.

    Bartels L, Remme WJ, Van der Ent M, Kruijssen D. ACE-inhibitors reduce myocardial ischemia through modulation of ischemia-induced catecholamine activation. Experience with perindoprilat (abstr).J Am Coll Cardiol 1993;21(suppl):19.

Download references

Author information

Correspondence to Willem J. Remme MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Venneker, E.H.G., Remme, W.J., van Hoogenhuyze, D.C.A. et al. Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease. Cardiovasc Drug Ther 8, 211–219 (1994). https://doi.org/10.1007/BF00877329

Download citation

Key Words

  • epanolol
  • beta-blockers
  • intravenous
  • hemodynamic
  • antiischemic
  • myocardial ischemia